Contrasting of Adaptive Biotechnologies Corporation (ADPT) and Novo Nordisk A/S (NYSE:NVO)

Both Adaptive Biotechnologies Corporation (NASDAQ:ADPT) and Novo Nordisk A/S (NYSE:NVO) are Biotechnology companies, competing one another. We will contrast their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Adaptive Biotechnologies Corporation 28 0.00 61.12M -0.44 0.00
Novo Nordisk A/S 55 2.45 1.68B 2.37 20.21

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Adaptive Biotechnologies Corporation and Novo Nordisk A/S.

Profitability

Table 2 demonstrates the net margins, return on equity and return on assets of Adaptive Biotechnologies Corporation and Novo Nordisk A/S.

Net Margins Return on Equity Return on Assets
Adaptive Biotechnologies Corporation 220,172,910.66% 0% 0%
Novo Nordisk A/S 3,030,849,720.37% 78.3% 36%

Liquidity

The Current Ratio and Quick Ratio of Adaptive Biotechnologies Corporation are 7.3 and 7.1 respectively. Its competitor Novo Nordisk A/S’s Current Ratio is 1 and its Quick Ratio is 0.7. Adaptive Biotechnologies Corporation can pay off short and long-term obligations better than Novo Nordisk A/S.

Analyst Ratings

In next table is given Adaptive Biotechnologies Corporation and Novo Nordisk A/S’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Adaptive Biotechnologies Corporation 0 0 0 0.00
Novo Nordisk A/S 0 1 0 2.00

Meanwhile, Novo Nordisk A/S’s average price target is $400, while its potential upside is 597.47%.

Institutional and Insider Ownership

Institutional investors owned 46.2% of Adaptive Biotechnologies Corporation shares and 9.8% of Novo Nordisk A/S shares. Insiders owned 4.7% of Adaptive Biotechnologies Corporation shares. Insiders Comparatively, owned 26.4% of Novo Nordisk A/S shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Adaptive Biotechnologies Corporation -4.53% -3.87% 0% 0% 0% -4.34%
Novo Nordisk A/S -3.25% -6.99% -2.46% 1.85% -5.5% 4.02%

For the past year Adaptive Biotechnologies Corporation has -4.34% weaker performance while Novo Nordisk A/S has 4.02% stronger performance.

Summary

Novo Nordisk A/S beats Adaptive Biotechnologies Corporation on 11 of the 12 factors.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity Care, and Biopharmaceuticals. The Diabetes and Obesity Care segment provides insulins, GLP-1 analog, and oral anti-diabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.